A strategy to replace the ethylamine side chain of 2,5-dimethoxy-4- iodoamphetamine (DOI, 1a), and 2,5-dimethoxy-4-bromoamphetamine (DOB, 1b) with a cyclopropylamine moiety was successful in leading to compounds with high affinity at the 5-HT 2 family of receptors; and the more potent stereoisomer of the cyclopropane analogues had the expected (-)-(1R,2S)- configuration. Screening for affinity at various serotonin receptor subtypes, however, revealed that the cyclopropane congeners also had increased affinity at several sites in addition to the 5-HT 2A and 5-HT 2B receptors. Therefore, at appropriate doses - although (-)-4 and (-)-5 may be useful as tools to probe 5-HT 2 receptor function - one would need to be mindful that their selectivit...
A conformationally restricted analog of a selective cyclopropane-bearing serotonin 2C agonist was de...
2-[5-[[(Trifluoromethyl)sulfonyl]oxy]-1H-indol-3-yl]ethylamine (18), its N,N-di-n-propyl (12), N,N-d...
(Chemical Equation Presented) Treating neurological conditions: Optimization of a previously identif...
A strategy to replace the ethylamine side chain of 2,5-dimethoxy-4-iodoamphetamine (DOI, 1a), and 2,...
A strategy to replace the ethylamine side chain of 2,5-dimethoxy-4-iodoamphetamine (DOI, 1a), and 2,...
A new series of fluorinated 5-HT2C agonists were designed and synthesized on the basis of our previo...
The discovery of a new series of compounds that are potent, selective 5-HT2C receptor agonists is de...
We report here the design, synthesis, and pharmacological properties of a series of compounds relate...
The 5-HT2C receptor is an attractive drug target in the quest for new therapeutics to treat a variet...
A series of N-benzylated-5-methoxytryptamine analogues was prepared and investigated, with special e...
A series of N-substituted (2-phenylcyclopropyl)methylamines were designed and synthesized, with the ...
A series of N-benzylated-5-methoxytryptamine analogues was prepared and investigated, with special e...
A series of novel ligands for the serotonin 5-HT2A/C receptor subtype bearing the 2-phenylethylamine...
The discovery of a new series of compounds that are potent, selective 5-HT2C receptor agonists is de...
Serotonin (5-HT) receptors represent a class of receptors involved in a variety of physiological pro...
A conformationally restricted analog of a selective cyclopropane-bearing serotonin 2C agonist was de...
2-[5-[[(Trifluoromethyl)sulfonyl]oxy]-1H-indol-3-yl]ethylamine (18), its N,N-di-n-propyl (12), N,N-d...
(Chemical Equation Presented) Treating neurological conditions: Optimization of a previously identif...
A strategy to replace the ethylamine side chain of 2,5-dimethoxy-4-iodoamphetamine (DOI, 1a), and 2,...
A strategy to replace the ethylamine side chain of 2,5-dimethoxy-4-iodoamphetamine (DOI, 1a), and 2,...
A new series of fluorinated 5-HT2C agonists were designed and synthesized on the basis of our previo...
The discovery of a new series of compounds that are potent, selective 5-HT2C receptor agonists is de...
We report here the design, synthesis, and pharmacological properties of a series of compounds relate...
The 5-HT2C receptor is an attractive drug target in the quest for new therapeutics to treat a variet...
A series of N-benzylated-5-methoxytryptamine analogues was prepared and investigated, with special e...
A series of N-substituted (2-phenylcyclopropyl)methylamines were designed and synthesized, with the ...
A series of N-benzylated-5-methoxytryptamine analogues was prepared and investigated, with special e...
A series of novel ligands for the serotonin 5-HT2A/C receptor subtype bearing the 2-phenylethylamine...
The discovery of a new series of compounds that are potent, selective 5-HT2C receptor agonists is de...
Serotonin (5-HT) receptors represent a class of receptors involved in a variety of physiological pro...
A conformationally restricted analog of a selective cyclopropane-bearing serotonin 2C agonist was de...
2-[5-[[(Trifluoromethyl)sulfonyl]oxy]-1H-indol-3-yl]ethylamine (18), its N,N-di-n-propyl (12), N,N-d...
(Chemical Equation Presented) Treating neurological conditions: Optimization of a previously identif...